Benjamin Edwards Inc. Acquires 22,257 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Benjamin Edwards Inc. increased its stake in Pfizer by 18.1% during the first quarter, owning 145,526 shares valued at approximately $3.69 million.
• Pfizer recently reported earnings of $0.78 per share for the last quarter, surpassing estimates, and had a revenue of $14.65 billion.
• The company announced a quarterly dividend of $0.43 per share, representing an annualized dividend yield of 7.0% with a payout ratio of 91.49%.

Benjamin Edwards Inc. raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 18.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 145,526 shares of the biopharmaceutical company's stock after purchasing an additional 22,257 shares during the quarter. Benjamin Edwards Inc.'s holdings in Pfizer were worth $3,688,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Rockefeller Capital Management L.P. boosted its position in shares of Pfizer by 2.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,665,404 shares of the biopharmaceutical company's stock worth $44,189,000 after purchasing an additional 35,315 shares in the last quarter. Sagespring Wealth Partners LLC purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $1,117,000. Finally, WealthTrust Axiom LLC increased its position in Pfizer by 10.7% during the 4th quarter. WealthTrust Axiom LLC now owns 197,648 shares of the biopharmaceutical company's stock valued at $5,244,000 after buying an additional 19,035 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PFE shares. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. TD Cowen dropped their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic dropped their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Finally, Leerink Partners dropped their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

PFE traded up $0.06 during trading on Tuesday, hitting $24.64. The company's stock had a trading volume of 34,400,469 shares, compared to its average volume of 47,175,628. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The firm has a market cap of $140.06 billion, a PE ratio of 13.10, a P/E/G ratio of 0.88 and a beta of 0.52. The business's 50 day simple moving average is $24.46 and its 200-day simple moving average is $24.47.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.60 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.